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Justificativa e Objetivos: No contexto da pandemia de COVID-19, em que a principal 
rota de transmissão da doença se dá pelo contato com saliva contaminada, procedimentos 
odontológicos de rotina representam um risco potencial de contágio para profissionais e 
pacientes. Para diminuir a ocorrência de infecção cruzada, são necessárias formas de 
controle da carga microbiana oral, como o uso de enxaguantes bucais pré-operatórios. 
Dessa forma, o objetivo desta revisão de literatura foi avaliar a potencial eficácia de 
diferentes antissépticos intraorais no controle de infecção por SARS-CoV-2 na clínica 
odontológica. Conteúdo: Trata-se de uma revisão da literatura, realizada nas bases de 
dados LILACS, Biblioteca Cochrane, CAPES e MEDLINE, através dos termos de busca 
“mouth rinse”, “dental care”, “COVID-19”, “cetylpiridinium cloride”, “povidone-
iodine”, “chlorhexidine” e “hydrogen peroxide”. Entre os 46 artigos potencialmente 
relevantes, foram selecionados 14 artigos, com textos completos publicados, nos últimos 
5 anos. Esses foram analisados e categorizados conforme o tipo de estudo (revisão de 
literatura, estudos in vitro e estudos in vivo). Os antissépticos destacados como mais 
relevantes em termos de eficácia antiviral foram iodopovidona, cloreto de cetilpiridínio, 
peróxido de hidrogênio e clorexidina. Conclusão: Poucas evidências foram encontradas 
em relação à eficácia de antissépticos orais contra o SARS-CoV-2. Vale ressaltar que 
alguns estudos realizados com iodopovidona e clorexidina demonstram resultados 
promissores no combate à infecção pelo SARS-CoV-2. Contudo, a realização de estudos 
clínicos randomizados é de extrema importância para determinar a eficácia desses 
compostos no controle da COVID-19 na prática odontológica.  




Background and Objectives: In the context of the COVID-19 pandemic, in which the 
main route of transmission is through contact with contaminated saliva, routine dental 
 
 
procedures represent a potential risk of contagion for professionals and patients. To 
reduce the occurrence of cross-infection, ways of controlling oral microbial load are 
necessary, such as the use of preoperative mouthwashes. Thus, the aim of this literature 
review was to assess the potential efficacy of different intra-oral antiseptics in SARS-
CoV-2 infection control in dental clinics. Content: This is a literature review, carried out 
in the LILACS, Cochrane Library, CAPES and MEDLINE databases, using the search 
terms “mouth rinse”, “dental care”, “COVID-19”, “cetylpiridinium chloride”, “povidone-
iodine”, “chlorhexidine”, and “hydrogen peroxide”. Among the 46 potentially relevant 
articles, fourteen articles were selected, with full texts published in the last 5 years. These 
were analyzed and categorized according to the type of study (literature review, in vitro 
and in vivo studies). The antiseptics highlighted as most relevant in terms of antiviral 
efficacy were povidone-iodine, cetylpyridinium chloride, hydrogen peroxide and 
chlorhexidine. Conclusion: Little evidence has been found regarding the effectiveness of 
oral antiseptics against SARS-CoV-2. It is worth mentioning that some studies conducted 
with povidone-iodine and chlorhexidine show promising results in combating SARS-
CoV-2 infection. However, conducting randomized clinical studies is extremely 
important to determine the effectiveness of these compounds in controlling COVID-19 in 
dental practice. 




Justificación y objetivos: En el contexto de la pandemia de COVID-19, en la que la 
principal vía de transmisión de la enfermedad es a través del contacto con saliva 
contaminada, los procedimientos dentales representan un riesgo de contagio para 
profesionales y pacientes. Para reducir la infección cruzada, son necesarias formas de 
controlar la carga microbiana oral, como el uso de enjuagues bucales preoperatorios. Por 
lo tanto, el propósito de esta revisión de la literatura fue evaluar la efectividad de 
diferentes antisépticos intraorales para controlar la infección por SARS-CoV-2 en la 
clínica dental. Contenido: Esta es una revisión de la literatura, realizada en las bases de 
datos LILACS, Cochrane Library, CAPES y MEDLINE, utilizando los términos de 
búsqueda “mouth rinse”, “dental care”, “COVID-19”, “cetylpiridinium cloride”, 
“povidone-iodine”, “chlorhexidine” y “hydrogen peroxide”. Entre los 46 artículos 
potencialmente relevantes, se seleccionaron 14 artículos, con textos completos publicados 
en los últimos 5 años. Estos fueron analizados y categorizados según el tipo de estudio 
(revisión de la literatura, estudios in vitro y in vivo). Los antisépticos destacados como 
más relevantes en términos de eficacia antiviral fueron povidona yodada, cetilpiridinio 
cloruro, peróxido de hidrógeno y clorhexidina. Conclusión: Se encontró poca evidencia 
con respecto a la efectividad de los antisépticos orales contra el SARS-CoV-2. Vale la 
pena mencionar que algunos estudios realizados con povidona yodada y clorhexidina 
muestran resultados prometedores contra el SARS-CoV-2. Sin embargo, realizar estudios 
clínicos aleatorios es importante para determinar la efectividad de estos compuestos en el 
control de COVID-19 en la práctica dental. 











The first cases of infection by the new human coronavirus (SARS-CoV-2) were 
registered in December 2019 in the city of Wuhan, China.1 The virus belongs to the family 
Coronaviridae, the same as the etiological agents of Severe Acute Respiratory Syndrome 
(SARS-CoV) and the Middle East Respiratory Syndrome (MERS-CoV). COVID-19, a 
frequently asymptomatic but potentially lethal disease, has spread throughout the 
world.2,3 Given its vertiginous spread, the World Organization of Health (WHO) declared 
COVID-19 a global pandemic on March 11, 2020. 
SARS-CoV-2 has a positive and unique RNA strand as its genome.4 It is a virus 
whose lipid envelope composition has not yet been determined experimentally, but it is 
known to be similar to influenza and herpes simplex viruses, containing 
phosphorylcholine, cholesterol, sphingolipids and “spike” glycoproteins.5 The latter are 
essential for the binding of the micro-organism with the host cells, contributing to its high 
degree of infectivity.5 
Although its incubation period is estimated to be long, between 2 to 14 days, any 
infected individual can transmit the disease, even before the onset of symptoms.6-8 This 
is because, in the first 10 days after infection, it still in the asymptomatic phase, the virus 
accumulates in the nasal and oropharyngeal mucosa, in addition to the salivary glands, in 
whose cells there is a high expression of the transmembrane protein angiotensin-
converting enzyme 2 (ACE2), the main receptor of SARS-CoV-2 in the cells.9 It is 
inferred , furthermore, that its expression in the salivary glands is greater than in the lungs, 
which suggests that these sites are reservoirs for the virus before they infect other organs 
such as lungs, kidneys, and heart.10 
This factor gives saliva a high viral load, which can reach 1.2 × 108/ml of 
infectious copies, which makes it play a crucial role in the disease transmission route.11 
In this regard, the current pandemic resulted in many implications for dental practice, 
since professionals need to be in constant contact with patients’ oral fluids, including 
saliva and even blood. Moreover, some dental procedures that require the use of water 
jets, ultrasonic scrapings and low and high-speed handpieces release small saliva particles 
(≤ 5 μm), also known as aerosols, into the medium, which can transport SARS-CoV-2 as 
well as other pathogens.12,13 In general, aerosols have delayed stabilization, which causes 
them to remain suspended in the air for a period of up to 4 hours after the procedures, in 
 
 
addition to possibility of being transported over distances greater than one meter and 
eighty.14,15 
In fact, to mitigate cross-infection resulting from contact with contaminated 
aerosols, it is possible to reduce their production, with the replacement of motorized 
instruments by manuals or reducing the salivary microbial load through the use of 
preoperative oral antiseptics.4 However, in certain cases, high-speed engines and water 
jets are essential for carrying out the procedures. Therefore, the use of antiseptics is 
essential to reduce the risk of disease transmission in dental clinics.12 
One of the most used oral antiseptics in dentistry is chlorhexidine gluconate 
(0.12%), due to its low toxicity and inhibition of oral biofilm development.16 However, 
the National Health Commission of China, through the Diagnosis Directive and 
Treatment of new Coronavirus Pneumonia, recommended the replacement of the 
compound by other antiseptics, as previous studies in the United States and England 
showed that its virucidal potential is limited and little known.4,17 Thus, many researchers 
have sought to assess the effectiveness and mechanism of action of other antiseptics that 
can help control the disease, such as povidone iodine (PVP-I), cetylpyridinium chloride 
(CPC) and hydrogen peroxide (H2O2), compounds that are already present in the chemical 
composition of many commercially available mouthwashes.2.18 
The Brazilian National Health Regulatory Agency (Anvisa - Agência Nacional de 
Vigilância Sanitária), as well as the Federal Council of Dentistry (CFO – Conselho 
Federal de Odontologia), have recommended mouthwashes with PVP-I (0.2%) or H2O2 
(0.5% to 1.5%) before the procedures as a complement to the traditional protocol of oral 
rinses with chlorhexidine (CHX).19,20 On the other hand, the Brazilian Association of 
Dental Education (ABENO - Associação Brasileira Ensino Odontológico) maintains the 
use of CHX as the main antiseptic and only indicates PVP- I (0.2%) and CPC in a titration 
of 1:4.000 in cases of allergic sensitivity.21 It is noteworthy that such recommendations 
are made based on the mechanism of action of these antiseptics, since their effectiveness 
against the new coronavirus is still has not been clinically proven.3 
Therefore, the present literature review aimed to assess the potential efficacy of 








This study is a descriptive and qualitative literature review. The literature review 
text was structured according to the PRISMA items 35 (Main Items for Reporting 
Systematic Reviews and Meta-analyses), checklist and flowchart for systematic reviews. 
 
Eligibility criteria 
Articles with publication date referring to the last five years, which had their full 
texts published in English and which addressed the efficacy of intraoral antiseptics in 
SARS-CoV-2 infection control in dental clinics were considered for this review. 
 
Exclusion criteria 
Editorials and studies that were based on the authors’ perspectives and that did 
not address the scientific knowledge regarding the efficacy of intraoral antiseptics in 
SARS-CoV-2 infection control in dental clinics were excluded. 
 
Information source and search strategy 
The databases used in this review included the Latin American and Caribbean 
Literature on Health Sciences (LILACS), the Cochrane Library, the CAPES Journal 
Portal, in addition to the Online System for Search and Analysis of Medical Literature 
(MEDLINE). The following search terms were used “mouth rinse”, “dental care”, 
“COVID-19”, associated by the Boolean operator AND, and “cetylpyridinium chloride”, 
“povidone-iodine”, “chlorhexidine” and “hydrogen peroxide”, these, in turn, are 
associated by the OR operator. A bibliographic search was carried out from June 30 to 
July 7, 2020. 
 
Selection of studies 
In phase 1, three reviewers (F.A.S.M., G.O.J. and A.V.R.F.) selected the articles 
independently. Disagreements were discussed and sorted out with a fourth reviewer 
(E.A.A.). Duplicate articles, which were in different databases, were excluded from the 
review. Articles that appeared to meet the inclusion criteria, as well as articles that lacked 
information in their abstracts, were selected for full reading in phase 2, in order to 
determine the work eligibility. A supplementary article was included after checking the 
reference lists. Data extraction and assessment of the quality of evidence were performed 
 
 
using the GRADE method 36 (Grading of Recommendations Assessment, Developing and 
Evaluation) in studies that met the inclusion criteria. 
Data collection 
Three reviewers (F.A.S.M., G.O.J. and A.V.R.F.) independently collected all data. 
The differences were discussed with a fourth reviewer (E.A.A.). Data were extracted and 
organized into tables. The following variables were verified: country and place of study, 
n sample, study design, antiseptic used (including concentration and duration of 
treatment), antiviral potential against SARS-CoV-2, and authors’ conclusions. 
Data were expressed as antimicrobial potential of the antiseptic (family 
Coronaviridae and other viruses) for the literature reviews included in the study. For in 
vitro and in vivo studies, the antiviral potential of the antiseptic against SARS-CoV-2 was 
analyzed. 
 
Risk of bias in individual studies 
The reviewers (F.A.S.M., G.O.J. and A.V.R.F.) performed an analysis of the 
articles independently and any disagreement was sorted out by consulting a fourth 
reviewer (E.A.A.). The GRADE method (Grading of Recommendations Assessment, 
Developing and Evaluation) was used to assess the quality of evidence in literature 
reviews and in vitro and in vivo studies regarding the antiviral activity of antiseptics 
against SARS-CoV-2. The quality of evidence was checked based on risk of bias, 
inconsistency, indirect evidence, and inaccuracy. 
 
RESULTS AND DISCUSSION 
 
Selection of studies 
In the first stage of the article selection process, 46 potentially relevant articles 
were selected from the Latin American and Caribbean Literature in Health Sciences 
(LILACS) electronic, Cochrane Library, CAPES Journal Portal, in addition to the System 
Online Search and Analysis of Medical Literature (MEDLINE) databases. After 
reviewing titles and abstracts, 19 articles were excluded as they were in different 
databases. The abstracts of the remaining 27 articles were read; however, 7 articles were 
excluded because they were not related to the review topic. Among the 20 selected 
articles, 7 did not meet the inclusion criteria of this review and were excluded. Thirteen 
 
 
articles were included and 1 complementary article selected after checking the reference 
lists, totaling 14 articles (Figure 1). 
 
 
Figure 1. Flowchart of included studies according to search strategy 
 
Studies included 
The characteristics of studies included in this review are shown in Tables 1, 2 and 
3. These were subdivided into three categories: literature reviews (Table 1), in vitro 
experimental studies (Table 2), and in vivo experimental studies (Table 3). 
 
Table 1. Selected literature reviews according to authorship, analyzed antiseptics and antimicrobial 
potential, n=9 
 
Authors Country Analyzed 
antiseptics  
Results: Antimicrobial Potential 
Herrera et al.; 
20202 
Germany CHX, PVP-I, 
CPC, and 
H2O2. 
CHX: Rapid inactivation of lipophilic viruses. 
PVP-I: Effective against enveloped and non-enveloped 
viruses. 
CPC: Effective against enveloped influenza viruses such as 
H1N1 and MERS-CoV. 
H2O2: Recommended use for its oxidizing activity, no 







CHX: Effective against enveloped viruses. A combination 
of CHX and ethanol is recommended to reduce the viral load 
of coronavirus species. 
 
 
0.23% PVP-I showed similar efficacy against SARS-CoV to 
that of ethanol (70%). 
H2O2: Disruption of lipid membranes by the release of 
oxygen free radicals. Little damage is reported within the 
range of 1 to 3%, concentrations used for tooth whitening. 
Marui et al.; 
201912 
Brazil CHX and 
CPC. 
CHX and CPC: No significant differences between them in 
the elimination of microorganisms from saliva aerosols. 
Ge et al.; 
202013  
China CHX and 
CPC. 
CHX 0.12%, which has already been shown to be effective 
against several infectious enveloped viruses. 
Use of 0.05% CPC for patients with CHX allergy. 
Parhar et al.; 
202017 
USA CHX and 
PVP-I. 
CHX: In vitro studies on inanimate surfaces showed that 
coronavirus species were sensitive to CHX in combination 
with ethanol or cetrimide. 
Povidone iodine (0.23%): 99.99% reduction of influenza A 
viruses, SARS-CoV-1 and MERS-CoV. 
Kanagalinga
m et al.; 
201523 
Singapore PVP-I. Virucidal activity greater than CHX. Potential antiseptic for 
SARS-CoV control. 
Frank et al.; 
20203 
USA PVP-I. Virucidal antiseptic fast-acting, effective against SARS-
CoV and MERS-CoV. 
Baker et al.; 
202024 
USA CPC. CPC has a similar mechanism of action to some drugs that 
are effective against SARS-CoV-2. 
Caruso et al.; 
202025 
Italy H2O2. H2O2 nose/mouth/throat rinsing can improve local innate 
responses to viral infections and help protect against the new 
coronavirus (SARS-CoV-2). 
Source: The authors (2021). 
 
Table 2. In vitro studies selected according to authorship, analyzed antiseptics, characterization of samples 
and antiviral potential against SARS-CoV-2, n=2 
 
Articles Country Analyzed 
antiseptics  








Antiseptic and virus 
solutions were 
incubated at room 
temperature (22ºC) for 
15 and 30s. Negative 
control (water). 
PVP-I at the 3 concentrations 
completely inactivated the SARS-CoV-
2 present in the samples in the time 
periods of 15s and 30s. 
H2O2, at concentrations of 1.5% and 





USA PVP-I (0.5%, 1%, 
1.5%) and 
ethanol (70%). 
Antiseptic and virus 
solutions were 
incubated at room 
temperature (22ºC) for 
15 and 30s. Negative 
control (water). 
PVP-I at the 3 concentrations showed 
similar virucidal potential over the same 
period of time (15s), with complete 
virus inactivation. Cytotoxicity was not 
observed. 
Ethanol (70%) took twice as long as 
PVP-I to completely inactivate the virus 
(30s). 







Table 3. In vivo studies selected according to authorship, analyzed antiseptics, sample characterization and 
antiviral potential against SARS-CoV-2, n=3 











Saliva samples were 
collected 1h, 2h and 
4h after rinsing with 
CHX. 
The viral load in 
saliva decreased 
significantly and 











Saliva samples were 
collected 5min, 1h, 2h 
and 4h after PVP-I 
mouthwash. 
In all samples, SARS-
CoV-2 was present. 
Most showed a 
decrease only after 1 












Patients gargled with 
PVP-I for 30s before 
the test. 
Antiviral potential has 
not been analyzed. 
Source: The authors (2021). 
 
After analyzing the articles, it was possible to identify four most relevant 
antiseptics in oral viral load control: CHX, PVP-I, CPC, and H2O2. 
 
Chlorhexidine (CHX) 
One of the most common antiseptics in dental clinics, CHX has been 
recommended for medicinal use since the 1950s, being frequently used to control dental 
biofilm and treat gingivitis.17,30 In low concentrations (0.12%), it has bacteriostatic effect; 
in higher concentrations (2%), it has bactericidal effect.30 Its mechanism of action 
involves the lysis of the bacterial cell wall, which usually occurs after thirty seconds of 
application.4,17 It has its proven efficacy against gram-positive and gram-negative 
bacteria, aerobics and anaerobics.2 
However, its virucidal effects are controversial according to the analysis of the 
results obtained (Tables 1 and 3). Among the nine literature reviews selected, five 
addressed CHX characteristics.2,5,12,13,17 In general, all articles reported its efficacy 
against lipophilic or enveloped viruses, but not against non-enveloped ones. Experimental 
studies proving the inactivation of coronavirus species are still scarce.2 However, two 
more recent articles reported that coronavirus species showed sensitivity when subjected 
to the application of CHX solution combined with other compounds, such as ethanol 
(70%) and cetrimide on inanimate surfaces (Table 1).5,10 
Regarding the elimination of microorganisms present in aerosols, CHX was 
potentially less effective than PVP-I, having similar efficacy to CPC.12,17 However, an in 
 
 
vivo study carried out with two patients affected by COVID-19, who were given 
mouthwash for 30s with 15 mL of 0.12% CHX gluconate, showed that the viral load of 
SARS-CoV-2 in saliva significantly decreased and maintained is stable for 2 hours after 
application (Table 3). 
 
Povidone iodine (PVP-I) 
PVP-I is used in dentistry for oral decontamination, periodontal and peri-implant 
treatment, in addition to post-tooth extraction therapy.27 However, its use is restricted, 
being contraindicated for individuals with iodine allergy, pregnant women, with thyroid 
disease active and patients on radioactive iodine therapy, as allergic reactions and thyroid 
dysfunctions have already been reported.27,31 
Its mechanism of action occurs through the release of free iodine, which interrupts 
microbial metabolic pathways, destabilizes the structural components of cell membranes 
and leads to irreversible damage to pathogens, as it oxidizes nucleic acid molecules.3,18 It 
has proven efficacy against species of influenza, such as H1N1, since it acts to block viral 
activity by inhibiting hemagglutinin and neuraminidases proteins, thus preventing the 
binding of the virus to cell receptors as well as the release of the viral particle and 
consequent infection of new cells.3 
The results showed that five review articles indicated the potential efficacy of 
PVP-I against coronavirus species (Table 1), given that it is characterized by having a 
larger viral spectrum than CHX, acting against enveloped or non-enveloped viruses.2 
,3,5,17,23 Furthermore, three in vitro studies demonstrated the inactivation of SARS-CoV 
and MERS-CoV by the antiseptic.2,17,18 Although allergic reactions have been pointed out 
by some studies, other studies did not find them in the literature evidence of mucosal 
toxicity or irritation, even with prolonged use (Table 1).2,3,5,17,31 
Regarding SARS-CoV-2, the two in vitro studies already carried out applied 
different concentrations of PVP-I to virus samples grown in cell media (Table 2). 
Antiseptic and virus solutions were incubated at room temperature (22ºC) for 15 and 30s. 
Thus, it was observed that PVP-I was able to completely inactivate the virus after 15 
seconds of application, at concentrations of 0.5%, 1%, 1.25% and 1.5%, with no 
cytotoxicity being observed. 26.27 
On the other hand, only one of the two selected in vivo studies assessed the 
virucidal potential of PVP-I (1%) (Table 3). This did not demonstrate a significant 
antiseptic efficacy against the new coronavirus, since a considerable reduction in viral 
 
 
activity in saliva only occurred in 75% of patients assessed and only 1 h after its 
application (Table 3).29 There were no reports of allergic reactions after rinsing with PVP-
I in 0.5% and 1% titrations.29,30 
 
Cetylpyridinium chloride (CPC) 
CPC is a quaternary ammonium cation, soluble in water and highly cationic at 
neutral pH.2 It belongs to the group of surface-active agents and is often found in oral 
antiseptics and disinfectants.2,24 Furthermore, it is important in dentistry for its 
antibacterial, antiplaque and antigenivitis properties.24 
The virucidal effect of CPC occurs mainly against enveloped viruses by releasing 
cations that act by breaking the lipid envelope, thus preventing cell infection.32 Its 
spectrum of action includes influenza virus strains (H1N1, AH3N2, A, B and A resistant 
to oseltamivir), respiratory syncytial virus, parainfluenza and HIV (Table 2).3,12,13,22,24 
The action of CPC against coronaviruses was recently demonstrated.34 Of the 36 
antiseptics tested by Shen et al. (2019), CPC was ranked the ninth most relevant against 
four species of coronaviruses, including the virus that causes MERS.33.34 
There are no records of in vitro or in vivo experiments verifying the effectiveness 
of CPC against SARS-CoV-2. However, due to its mechanism of action, which is similar 
to that of some drugs used against the new coronavirus, the use of CPC-based 
mouthwashes is recommended in case of any need to change the traditional preoperative 
protocol (CHX 0.12%), as in patients allergic to CHX.13,24 The occurrence of allergic 
reactions to CPC is rare, although there are reports of pigmentation of the tongue and 
teeth.23 
 
Hydrogen peroxide (H2O2) 
Widely used in concentrations at 1 to 3% as a tooth whitening agent, H2O2 causes 
disruption of lipid membranes by releasing oxygen free radicals, making it very effective 
against enveloped viruses.2,5 
Although higher concentrations (> 5%) can induce damage to soft and hard tissues 
of the body, little damage is reported within the concentration range used in dental 
clinics.5 In addition to this, its inactivation in the oral mucosa is rapid due to the presence 
of catalase enzyme, physiologically produced by the body and by bacteria of the oral 
microbiota, which reduces its possibility of causing allergic reactions.5 
 
 
Some studies discussed the virucidal potential of H2O2, including three literature 
reviews and one in vitro study (Tables 1 and 2). Some authors recommended its use due 
to antioxidant properties.2,5,25 Caruso et al. (2020) highlighted that mouth and nasal rinses 
with antiseptic can improve the local innate response to viral infections due to oxidative 
stress caused by it (Table 1).25 
Regarding efficacy against SARS-CoV-2, Bidra et al. 2020 assessed the virucidal 
effect of H2O2 at two concentrations (1.5% and 3%), verifying a minimal reduction in 
viral titer after 30s of interaction of H2O2 with the virus (Table 2).
26 Thus, H2O2 was less 
effective than PVP-I used in the study, since PVP-I at concentrations of 0.5%, 1.25% and 
1.5% completely inactivated SARS-CoV-2 after 15s of interaction. 
 
Assessment of the quality of evidence (GRADE) 
Table 4 shows the assessment of the quality of evidence performed by the GRADE 
method.36 Literature reviews showed moderate quality of evidence due to the risk of bias 
in some selected articles. Although many articles discuss the relevance of antiseptic 
activity against viruses related to SARS-CoV-2 such as SARS-CoV and MERS-CoV, 
some studies do not present results in randomized clinical trials, with a significant number 
of patients.2,5,12,17,25 The absence of these data compromises the quality of evidence and 
can hinder decision-making related to the use of these antiseptics in dentists’ practice. 
Furthermore, the in vivo studies analyzed showed very low quality of evidence, 
presenting methodological limitations and inconsistency of results (Table 4). The very 
low quality of evidence is associated with a reduced number of subjects in the studies 
16,28, differences in the results presented by patients28 and the lack of testing to confirm 
the suggested results.29 Although the pandemic was a major factor for the development 
of research around the world, it is extremely important that other studies with a lower risk 
of bias are carried out to determine the real effectiveness of these intraoral antiseptics in 
COVID-19 control in dental clinics. 
On the other hand, in vitro studies showed high quality of evidence, demonstrating 
the antiviral activity of PVP-I against SARS-CoV-2.26,27 These data are promising and 
may contribute to future randomized clinical trials capable of investigating the action of 





Table 4. Assessment of the quality of evidence of the results found for efficacy of intraoral antiseptics in 
SARS-CoV-2 infection control in dental clinics 
CI: confidence interval; GRADE: Grading of Recommendations Assessment, Developing and Evaluation; IDCC: Infecting dose of 
50% of cell culture; VL: viral load.  




Routine dental procedures constantly release saliva aerosols containing pathogens 
into the medium, potentially increasing the risk of cross-infection. Therefore, considering 
that the main route of transmission of SARS-CoV-2 through contact with contaminated 
saliva, the use of preoperative oral antiseptics in dental clinics is essential to control 
transmission, as they can considerably decrease the salivary viral load. 
 Little conclusive evidence has been found regarding the efficacy of different oral 
antiseptics against SARS-CoV-2. However, PVP-I and CHX showed promising results 
in SARS-CoV-2 infection control in some studies. However, it is necessary to carry out 
randomized clinical studies to prove the real effectiveness of these antiseptics in 
combating SARS-CoV-2 infections. 
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